Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO					Complete if Known		
TRAU					Application Number	10/531,540	
INF	TRMATIC	ON D	וככו חפ	THE	Filing Date	April 15, 2005	
INFORMATION DISCLOSURE				:	First Named Inventor	Stanka PERC	
STATEMENT BY APPLICANT (Use as many sheets as necessary)					Art Unit		
					Examiner Name		
Sheet	1	of	2		Attorney Docket Number	4061-27PUS	

			U.S. PATEN	NT DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind-Code ^{2 (if} known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
	.,	US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
		US-			
		US-		***	·

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	T _e			
		Country Code ³⁻ Number ⁴⁻ Kind-Code ⁵ (if known	MM-DD-YYYY	Applicant of Cited Document					
· · · · · · · · · · · · · · · · · · ·				, ,					
				PALL L					
_									

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO					Complete if Known		
					Application Number	10/531,540	
INFO	RMATIO	N DI	SCI OS	HDF	Filing Date	April 15, 2005	
					First Named Inventor	Stanka PERC	
STATEMENT BY APPLICANT (Use as many sheets as necessary)					Art Unit		
	(Ose as many si	iccis as i	iccessary)		Examiner Name		
Sheet	2	of	2		Attorney Docket Number	4061-27PUS	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Third Party Observations to European Patent Application No. 03751723.2 of KRKA Tovarna Zdravil, D.D. Novo Mesto	
		Extract from US Food and Drugs Administration (FDA) Center for Durg Evaluation and Research, New and Generic Drug Approvals dated March 2000 and available from	
		http://web.archive.org/web/20001019042109/http://www.fda.gov/cder/approval/index.htm	
		ABPI Compendium of Data Sheets and Summaries of Products characteristics 1999-2000, Datapharm Publications Limited	
		Third Party Observations in respect of EP 1558219 A1 (WO 2004/035027 A1)	
	,		
	,		
170			
	ļ		

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.